Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2010

01-11-2010 | Original Article

Atorvastatin Induces Apoptosis In Vitro and Slows Growth of Tumor Xenografts but Not Polyp Formation in Min Mice

Authors: Emina H. Huang, Laura A. Johnson, Kathryn Eaton, Mark J. Hynes, Joseph E. Carpentino, Peter D. R. Higgins

Published in: Digestive Diseases and Sciences | Issue 11/2010

Login to get access

Abstract

Background

Despite the availability of effective surveillance for colorectal cancer with colonoscopy, relatively few at-risk individuals utilize this option. Colon cancer chemoprevention might be a more acceptable alternative. Some epidemiologic studies have suggested that statins may have chemopreventive effects without the risks of nonsteroidal anti-inflammatory drugs, but other epidemiologic studies have found no effect of statins.

Methods

We aimed to evaluate the efficacy of atorvastatin in inducing apoptosis in vitro, in preventing polyp formation in the min mouse, and in preventing tumor growth in nude mice.

Results

Atorvastatin rapidly induces apoptosis in the HCT116 colon cancer cell line in vitro, and this effect is reversible with mevalonate and geranylgeranyl pyrophosphate, but less so by farnesyl pyrophosphate. Atorvastatin chow was ineffective in reducing polyp formation in the min mouse model, with no significant effect on polyp number. Atorvastatin was effective in significantly slowing the growth of HCT116 colon cancer cell xenografts in nude mice (p = 0.008). Further, this reduction is due to increased levels of apoptosis.

Conclusions

Atorvastatin can induce apoptosis in vitro, through mevalonate and prenylation pathways. Atorvastatin, while not effective in preventing polyp formation in the min mouse model, was very effective in slowing tumor growth in a nude mouse model. Consistent with in vitro findings, increased apoptosis accounted for decreased tumor growth. Statins may have benefit in cancer by slowing tumor growth, rather than preventing tumor initiation.
Literature
2.
go back to reference Sewitch MJ, et al. Adherence to colorectal cancer screening guidelines in Canada. BMC Gastroenterol. 2007;7:39.CrossRefPubMed Sewitch MJ, et al. Adherence to colorectal cancer screening guidelines in Canada. BMC Gastroenterol. 2007;7:39.CrossRefPubMed
3.
go back to reference Yeazel MW, et al. Colorectal cancer screening adherence in a general population. Cancer Epidemiol Biomarkers Prev. 2004;13:654–657.PubMed Yeazel MW, et al. Colorectal cancer screening adherence in a general population. Cancer Epidemiol Biomarkers Prev. 2004;13:654–657.PubMed
4.
go back to reference American Cancer Society. Cancer facts and figures. 2008; a-70. American Cancer Society. Cancer facts and figures. 2008; a-70.
5.
go back to reference Farwell WR, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008;100:134–139.CrossRefPubMed Farwell WR, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008;100:134–139.CrossRefPubMed
6.
7.
go back to reference Blais L, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000;160:2363–2368.CrossRefPubMed Blais L, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000;160:2363–2368.CrossRefPubMed
8.
go back to reference Friis S, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114:643–647.CrossRefPubMed Friis S, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114:643–647.CrossRefPubMed
9.
go back to reference Kaye JA, Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer. 2004;90:635–637.CrossRefPubMed Kaye JA, Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer. 2004;90:635–637.CrossRefPubMed
10.
go back to reference Khurana V, et al. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest. 2007;131:1282–1288.CrossRefPubMed Khurana V, et al. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest. 2007;131:1282–1288.CrossRefPubMed
11.
go back to reference Bhuket TP, Higgins PD. Drug insight: statins and gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol. 2006;3:552–562.CrossRefPubMed Bhuket TP, Higgins PD. Drug insight: statins and gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol. 2006;3:552–562.CrossRefPubMed
13.
go back to reference Agarwal B, et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999;5:2223–2229.PubMed Agarwal B, et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999;5:2223–2229.PubMed
14.
go back to reference Kodach LL, et al. The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology. 2008;134:1332–1341.CrossRefPubMed Kodach LL, et al. The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology. 2008;134:1332–1341.CrossRefPubMed
15.
go back to reference Reddy BS, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res. 2006;66:4542–4546.CrossRefPubMed Reddy BS, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res. 2006;66:4542–4546.CrossRefPubMed
16.
go back to reference Couzin J. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science. 2004;306:384–385.CrossRefPubMed Couzin J. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science. 2004;306:384–385.CrossRefPubMed
17.
go back to reference Swamy MV, et al. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 2006;66:7370–7377.CrossRefPubMed Swamy MV, et al. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 2006;66:7370–7377.CrossRefPubMed
18.
go back to reference Baker SJ, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244:217–221.CrossRefPubMed Baker SJ, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244:217–221.CrossRefPubMed
19.
go back to reference Baker SJ, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990;50:7717–7722.PubMed Baker SJ, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990;50:7717–7722.PubMed
20.
go back to reference Bos JL, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327:293–297.CrossRefPubMed Bos JL, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327:293–297.CrossRefPubMed
21.
go back to reference Normanno N, et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol. 2009;6:519–527.CrossRefPubMed Normanno N, et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol. 2009;6:519–527.CrossRefPubMed
22.
go back to reference Schroy PC 3rd, et al. Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer. 1995;76:201–209.CrossRefPubMed Schroy PC 3rd, et al. Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer. 1995;76:201–209.CrossRefPubMed
23.
go back to reference Benvenuti S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643–2648.CrossRefPubMed Benvenuti S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643–2648.CrossRefPubMed
Metadata
Title
Atorvastatin Induces Apoptosis In Vitro and Slows Growth of Tumor Xenografts but Not Polyp Formation in Min Mice
Authors
Emina H. Huang
Laura A. Johnson
Kathryn Eaton
Mark J. Hynes
Joseph E. Carpentino
Peter D. R. Higgins
Publication date
01-11-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1157-x

Other articles of this Issue 11/2010

Digestive Diseases and Sciences 11/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.